Apricoxib

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Apricoxib
Apricoxib structure.svg
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H20N2O3S
Molar mass356.4387 g/mol g·mol−1
3D model (JSmol)

Apricoxib is an experimental anticancer drug. It is a COX-2 inhibitor which is intended to improve standard therapy response in molecularly defined models of pancreatic cancer.[1] Development was abandoned in 2015 due to poor clinical trial results.[2]

See also[edit]

References[edit]

  1. ^ Kirane, A. (2012). "Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer". Clinical Cancer Research. 18 (18): 5031–5042. doi:10.1158/1078-0432.CCR-12-0453. PMC 3777527. PMID 22829202.
  2. ^ http://adisinsight.springer.com/drugs/800026002